ATL-444

From WikiProjectMed
Jump to navigation Jump to search
ATL-444
Identifiers
  • (1S,3R)-1-[2-(6-amino-9-prop-2-ynylpurin-2-yl)ethynyl]-3-methylcyclohexan-1-ol
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC17H19N5O
Molar mass309.373 g·mol−1
3D model (JSmol)
  • C#CCN1C=NC2=C1N=C(C#C[C@@]3(CCC[C@H](C3)C)O)N=C2N
  • InChI=1S/C17H19N5O/c1-3-9-22-11-19-14-15(18)20-13(21-16(14)22)6-8-17(23)7-4-5-12(2)10-17/h1,11-12,23H,4-5,7,9-10H2,2H3,(H2,18,20,21)/t12-,17-/m1/s1
  • Key:VEJLEEFUXFQSHP-SJKOYZFVSA-N

ATL-444 is a drug which acts as a potent and reasonably selective antagonist for the adenosine receptors A1 and A2A. It has been used to study the role of the adenosine receptor system in the reinforcing action of cocaine,[1] as well as the development of some cancers.[2]

See also

References

  1. ^ Doyle SE, Breslin FJ, Rieger JM, Beauglehole A, Lynch WJ (August 2012). "Time and sex-dependent effects of an adenosine A2A/A1 receptor antagonist on motivation to self-administer cocaine in rats". Pharmacology, Biochemistry, and Behavior. 102 (2): 257–63. doi:10.1016/j.pbb.2012.05.001. PMC 3383440. PMID 22579716.
  2. ^ Choi MS, Moon SM, Lee SA, Park BR, Kim JS, Kim DK, Kim YH, Kim CS (May 2018). "Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells". Oncology Letters. 15 (5): 6489–6496. doi:10.3892/ol.2018.8089. PMC 5876434. PMID 29616118.